{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:32:32Z","timestamp":1781105552174,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81401796"],"award-info":[{"award-number":["81401796"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572267"],"award-info":[{"award-number":["81572267"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research and Development Projects of Jiangsu Province","award":["BE2017681"],"award-info":[{"award-number":["BE2017681"]}]},{"name":"Six Talent Peaks Program of Jiangsu Province","award":["WSW-038"],"award-info":[{"award-number":["WSW-038"]}]},{"name":"Jiangsu Post-doctoral Program","award":["1701008A"],"award-info":[{"award-number":["1701008A"]}]},{"name":"Jiangsu Youth Medical Talent Project","award":["QNRC2016702"],"award-info":[{"award-number":["QNRC2016702"]}]},{"name":"Nantong Science and Technology Project","award":["MS12017006-2"],"award-info":[{"award-number":["MS12017006-2"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.intimp.2018.12.034","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T03:43:01Z","timestamp":1547005381000},"page":"131-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma"],"prefix":"10.1016","volume":"68","author":[{"given":"Bo","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You Lang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8873-732X","authenticated-orcid":false,"given":"Ziheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3517-1881","authenticated-orcid":false,"given":"Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2018.12.034_bb0005","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2018.12.034_bb0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1634\/theoncologist.2015-0303","article-title":"The changing landscape of smoldering multiple myeloma: a European perspective","volume":"21","author":"Caers","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2018.12.034_bb0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fimmu.2015.00046","article-title":"Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment","volume":"6","author":"Aris","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/14737140.2015.1074862","article-title":"Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma","volume":"15","author":"Faghfuri","year":"2015","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.intimp.2018.12.034_bb0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: current status and future prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2018.12.034_bb0030","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2018.12.034_bb0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2018.12.034_bb0040","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2018.12.034_bb0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0055","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl","key":"10.1016\/j.intimp.2018.12.034_bb0060","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/jco.2013.31.15_suppl.3061","article-title":"Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models","volume":"31","author":"Selby","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0065","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2018.12.034_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.intimp.2018.12.034_bb0075","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.intimp.2018.12.034_bb0080","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.intimp.2018.12.034_bb0085","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.intimp.2018.12.034_bb0090","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0095","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0100","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2018.12.034_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2018.12.034_bb0110","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2018.12.034_bb0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2018.12.034_bb0120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(12)70324-8","article-title":"Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial","volume":"13","author":"Di Giacomo","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0125","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2018.12.034_bb0130","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00262-017-2030-y","article-title":"A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma","volume":"66","author":"Patel","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2018.12.034_bb0135","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0140","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.intimp.2018.08.014","article-title":"Immune-related adverse events from combination immunotherapy in cancer patients: a comprehensive meta-analysis of randomized controlled trials","volume":"63","author":"Zhang","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0145","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1200\/JCO.2014.56.6018","article-title":"Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial","volume":"33","author":"Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0150","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2018.12.034_bb0155","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/ijc.31252","article-title":"The efficacy and safety of anti-PD-1\/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer","volume":"142","author":"Xu","year":"2018","journal-title":"Int. J. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918308622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918308622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T02:08:33Z","timestamp":1606010913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576918308622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"alternative-id":["S1567576918308622"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2018.12.034","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2018.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}